These altered binding capabilities of margetuximab, particularly in cells with lower levels of HER2, in cells resistant to trastuzumab, and in patients bearing FcγRIIIA-V158F, result in increased ADCC and enhanced anti-tumor effects [73]. This evidence concerns the gene ERBB2 and neoplasm.